Novel Radiopharmaceutical Beats Cabazitaxel in mCRPC
A novel radiopharmaceutical was more active than cabazitaxel against metastatic castration-resistant prostate cancer (mCRPC) and caused fewer grade 3/4 adverse …
Home ยป
A novel radiopharmaceutical was more active than cabazitaxel against metastatic castration-resistant prostate cancer (mCRPC) and caused fewer grade 3/4 adverse …